Recruiting

AOSLO

Sponsor:

UCLA

Code:

NCT00254605

Conditions

Retinitis Pigmentosa

Eligibility Criteria

Sex: All

Age: 13+

Healthy Volunteers: Accepted

Study Details

Brief summary:

The purpose of this study is to determine whether the structure and function of the human retina can be studied with high resolution in patients with inherited retinal degenerations using the Adaptive Optics Scanning Laser Ophthalmoscope (AOSLO).

Conditions

Retinitis Pigmentosa

Study ID

NCT00254605

Start date

Nov 1, 2005

Status verified date

Jun, 2026

Completion date

Nov 1, 2028

Anticipated

Primary completion date

Oct 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 13+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Subjects must speak and understand English
  • Subjects must have pupils that dilate to at least 6 millimeters diameter.
  • Subjects must be willing to travel to University of California (UC) Berkeley.
  • Subjects are financially responsible for their travel to the San Francisco area if they are not San Francisco residents.

Exclusion Criteria:

  • Cataract
  • Irregular corneal astigmatism (keratoconus)
  • Prior refractive surgery

Study Design

Enrollment

400 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Cone spacing [ Time Frame: 24 months ]

Central Contacts and Locations

Central contacts

Jacque L. Duncan, M.D.

415-514-4241jacque.duncan@ucsf.edu

Locations

Department of Ophthalmology Retinal Degenerations Clinic, UCSF

Recruiting

San Francisco, California, United States, 94143

Contacts

Jacque Duncan, MD

415-514-4241jacque.duncan@ucsf.edu

More Information

Sponsor

University of California, San Francisco

Last update posted

Jun 5, 2026

Last verified

Jun, 2026

Keywords

  • imaging
  • adaptive optics scanning laser ophthalmoscope
  • optical coherence tomography
  • electroretinography

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-06-05.